June 8 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION TO THE FDA FOR METABLOK (LSALT PEPTIDE)
* ARCH BIOPARTNERS -SUBMITTED IND APPLICATION FOR METABLOK TO CONDUCT PHASE II TRIAL TO PREVENT ACUTE ORGAN INFLAMMATION, INJURY EXPERIENCED BY PATIENTS WITH COVID-19